RLAY Relay Therapeutics

Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights

Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, plans to report second quarter 2021 financial results after the close of market on Thursday, August 12, 2021. The company will not be conducting a teleconference in conjunction with its financial results press release.

About Relay Therapeutics



Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate technologies. The Company’s Dynamo™ platform integrates an array of leading-edge computational and experimental approaches to effectively drug protein targets that have previously been intractable. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease. For more information, please visit or .

Contact:

Pete Rahmer

Senior Vice President, Corporate Affairs and Investor Relations

617-322-0715

Media:

Dan Budwick

1AB

973-271-6085



EN
05/08/2021

Underlying

RLAYRelay Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relay Therapeutics

 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Participate in Two Upcoming Investor Conferences...

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in March: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. ETBarclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 at 10:30 a.m. ET The fireside c...

February 23, 2026 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Finan...

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report fourth quarter and full year 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 26, 2026. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-st...

February 19, 2026 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biot...

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Eve...

February 4, 2026 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy ...

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY),...

February 3, 2026 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (...

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mas...

December 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch